Analytical comparability to evaluate impact of manufacturing changes of ARX788, an Anti-HER2 ADC in late-stage clinical development

ARX788 is an anti-HER2 antibody drug conjugate (ADC) developed using Ambrx proprietary Engineered Precision Biologics technology. The manufacturing process of ARX788 has been optimized during the course of early to late-phase clinical development. A comprehensive evaluation of side-by-side comparabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Wayne, Ramprasad, Mysore P., Pal, Manoj, Chen, Chris, Paruchuri, Shashi, Skidmore, Lillian, Knudsen, Nick, Allen, Molly, Buechler, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332591/
https://www.ncbi.nlm.nih.gov/pubmed/37428761
http://dx.doi.org/10.1371/journal.pone.0284198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332591/
https://www.ncbi.nlm.nih.gov/pubmed/37428761
http://dx.doi.org/10.1371/journal.pone.0284198

Ejemplares similares